Physician profile
Vivienne Yoon
NPI 1689899221
$7,090.71
in general payments reported to CMS, 2019-2025
49 companies · $2,101 in 2025
The $2,101 reported for 2025 was more than what 77% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,619 · 2020: $95.89 · 2021: $45.53 · 2022: $458 · 2023: $1,492 · 2024: $1,279 · 2025: $2,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,803 · Education: $70.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,803.06 |
| Education | $70.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,287.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $709.59 | 2019-2025 | Evenity, Tepezza, Prolia |
| Lilly USA, LLC | $479.99 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Mannkind Corporation | $477.53 | 2019-2025 | Afrezza |
| Tandem Diabetes Care, INC. | $376.77 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $310.64 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Abbott Laboratories | $257.74 | 2022-2025 | Freestyle Libre 3 |
| Radius Health, INC. | $245.73 | 2019-2025 | Tymlos |
| Insulet Corporation | $240.38 | 2019-2025 | Omnipod |
| Neurocrine Biosciences, INC. | $198.13 | 2024-2025 | |
| Abbvie INC. | $180.78 | 2019-2025 | Synthroid |
| Corcept Therapeutics | $148.31 | 2024-2025 | Korlym |
| Beta Bionics, INC. | $141.76 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Bayer Healthcare Pharmaceuticals INC. | $140.33 | 2023-2025 | |
| Recordati_rare_diseases_inc. | $139.62 | 2023-2025 | Isturisa, Signifor Lar |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $129.13 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.98 | 2019-2025 | Jardiance |
| Medtronic, INC. | $97.57 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Ibsa Pharma INC. | $88.40 | 2019-2025 | Tirosint, Licart, Flector |
| Currax Pharmaceuticals LLC | $82.97 | 2023-2024 | Nexletol, Contrave |
| Pfizer INC. | $81.52 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $79.85 | 2023-2025 | Gvoke Hypopen |
| Vivus LLC | $72.95 | 2023-2024 | Qsymia |
| Acella Pharmaceuticals, LLC | $68.23 | 2023-2025 | NP Thyroid 60 |
| Merck Sharp & Dohme LLC | $65.05 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $63.19 | 2019-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $58.24 | 2019-2020 | |
| Soleno Therapeutics, INC. | $57.69 | 2025 | Vykat Xr |
| Amarin Pharma, INC. | $55.31 | 2019-2022 | |
| Embecta Corp. | $54.60 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Ascensia Diabetes Care US INC. | $46.48 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $43.22 | 2019-2024 | Unithroid |
| Ascendis Pharma Endocrinology INC | $41.85 | 2025 | Yorvipath |
| Sequel Med Tech, LLC | $41.00 | 2025 | Twiist |
| Becton, Dickinson and Company | $40.87 | 2022 | |
| Eisai INC. | $38.96 | 2019 | |
| Roche Diabetes Care, INC. | $37.32 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.54 | 2019-2023 | Cycloset |
| Cequr Corporation | $33.04 | 2022-2023 | Cequr Simplicity |
| Valeritas, INC. | $30.76 | 2019 | |
| Medtronic Minimed, INC. | $28.24 | 2019 | |
| Averitas Pharma INC. | $25.70 | 2025 | Qutenza |
| Companion Medical, INC. | $25.15 | 2019-2020 | |
| Kyowa Kirin, INC. | $24.61 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $23.56 | 2019 | |
| Zealand Pharma US, INC. | $19.81 | 2022 | |
| Tolmar, INC. | $19.17 | 2025 | Jatenzo |
| Lifescan, INC. | $16.34 | 2023 | |
| Esperion Therapeutics, INC. | $14.30 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivienne Yoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.